When Sarclisa was launched back in 2020, Sanofi hailed the multiple myeloma therapy as its return to oncology, but since then it has barely troubled its main rival, J&J and Genmab’s multi-billion blockbuster Darzalex.
Key Takeaways
-
Sarclisa is aiming to gain its first ever frontline approval in multiple myeloma
While Darzalex (daratumumab) is an established frontline treatment and earned $7.2bn in the first nine months of this year, Sarclisa...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?